Hua Medicine Subsidiary Huaota Announces HB0025, a Novel PD-L1/VEGF Bispecific Fusion Protein, Enters Pivotal Phase III Trial in Endometrial Cancer

▲August 1-22025 Biopharmaceutical Innovation ExpoScan to Register

Note:This article does not constitute any investment opinions or recommendations., subject to official/company announcementsAccurate；This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must be authorized.

PharmaCircleIt was reported that Huahai Pharmaceutical's subsidiary Huaota recently announced: its self-developedPD-L1/VEGFBispecific Fusion ProteinHB0025, Combined with standard treatment (SOC) for advanced or recurrent endometrial cancer, has been officially submitted toCDESubmission for ConfirmationIIIApplication for Pre-Phase Clinical Trial Initiation Meeting.

This drug achieves high-affinity binding to two targets through structural design, synergistically modulating the tumor immune microenvironment and angiogenesis.Immune Enhancement+Anti-vascular"Dual Anti-Tumor Mechanism.

https://pharma.bcpmdata.com/，Moxie Medical Data

Looking forward to more transactions in China, which has now becomeThe Cradle of Global Innovative Drugs。

Reference:

NMPA/CDE；

Moxie Pharma Data pharma.bcpmdata.com (formerly Pharma Intelligence Cloud Data);

FDA/EMA/PMDA；

Official Company;

Etc.

[ Co-Planner ]

 Xie Xuanhui, Chief Innovation and Investment Officer, Icarus Bio

◈ 09:00-09:30

Subject to be determined
Qilu Pharmaceutical

◈ 09:30-10:00

A New Generation of Topo1 Inhibitors - Solving the Challenge of Resistance to Existing Targeted Drugs and ADCs
Party and Masses
Real Biotech, President

◈ 10:00-10:30

Enhance ADC Efficacy, Explore Targets in New Spaces

Cai Jiaqiang

Suzhou Yilian Biotechnology, Co-Founder, CSO

◈ 10:30-11:00

Use of bispecific strategies to reduce the toxicity of ADCs
Dashi Pharmaceutical

◈ 11:00-11:30

Innovation and Future of Antibody-Drug Conjugates

Feng Zhenqing

Director of the Key Laboratory of Antibody Technology of the National Health Commission, Nanjing Medical University

◈ 11:30-12:10

Panel: Leading International Clinical Advances in Chinese Solid Tumors

[ Host ]

Yang Xiugao  CSPC, Senior Medical Director

[ Guest ]

Black YongjiangCSPC Group, Executive President & Global CMO

Yang JianxinCStone Pharmaceuticals, CEO & Executive Director

Zhu YonghongEpimAb Biotherapeutics, CMO

Zuo YunxiaVP of Clinical Development at BeiGene

Gao ChangshouElis Pharmaceuticals, Chief Technology Officer

◈ 12:10-13:30

Lunch Break

◈ 13:30-14:00

Subject to be determined

Guest Itinerary Confirmation in Progress

◈ 14:00-14:30

Innovation and Future Directions in ADC Drug Development
Guest Itinerary Confirmation in Progress

◈ 14:30-15:00

Progress in the Development of anti-TfR1 Antibody-Conjugated Oligonucleotides (Proposed)

Xuefeng Zhang

Caribio Biotech, Co-Founder/COO

◈ 15:00-15:30

ADC: Case Sharing from Project Initiation to Development
Bellez Pharmaceuticals

◈ 15:30-16:00

ADC Drug Development Iteration Strategy

Yan Bin

Head of Medici ADC Platform

◈ 16:00-16:30

Panel: ADC 3.0 Era: From Technological Competition to Ecosystem Reconstruction

[ Guest ]

Li HuInvestment Partner at Sequoia Capital, Executive Scientific Officer at Nuclear Ark Pharmaceuticals